<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03128320</url>
  </required_header>
  <id_info>
    <org_study_id>17500</org_study_id>
    <secondary_id>2015-003799-63</secondary_id>
    <nct_id>NCT03128320</nct_id>
  </id_info>
  <brief_title>The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure</brief_title>
  <official_title>A Randomized, Single-blind, Threefold Crossover, Single-center Study to Assess the Safety and the Effects of 1 mg and 5 mg BAY1193397 in Comparison to Placebo on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure After Single Dose in Type II Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to analyse skin blood flow in diabetic patients. The patients&#xD;
      receive a single dose of placebo, 1 mg BAY1193397, and 5 mg BAY1193397. The analysis of&#xD;
      safety and tolerability are secondary objectives of this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2017</start_date>
  <completion_date type="Actual">October 28, 2019</completion_date>
  <primary_completion_date type="Actual">September 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in resting capillary blood flow velocity (CBV)</measure>
    <time_frame>Before and after treatment with study drug (within 1-3 hours after treatment with study drug)</time_frame>
    <description>= resting CBV after study drug administration - resting CBV before study drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in peak CBV during reactive hyperemia</measure>
    <time_frame>Before and after treatment with study drug (within 1-3 hours after treatment with study drug)</time_frame>
    <description>= peak CBV after study drug administration - peak CBV before study drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in time to peak CBV during reactive hyperemia</measure>
    <time_frame>Before and after treatment with study drug (within 1-3 hours after treatment with study drug)</time_frame>
    <description>= time to peak CBV after study drug administration - time to peak CBV before study drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in transcutaneous oxygen pressure (TcPO2)</measure>
    <time_frame>Before and after treatment with study drug (within 1-3 hours after treatment with study drug)</time_frame>
    <description>= TcPO2 after study drug administration - TcPO2 before study drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From first application of study medication up to 2 days after end of treatment with study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with TEAEs in different severity</measure>
    <time_frame>From first application of study medication up to 2 days after end of treatment with study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Diabetic Foot</condition>
  <arm_group>
    <arm_group_label>BAY1193397/Placebo (sequence A-B-C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with type II diabetes who follow treatment sequence A-B-C. Single oral dose of a placebo tablet in the first intervention period (Treatment A); followed by single oral dose of 1 mg BAY1193397 (Treatment B); then single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1193397/Placebo (sequence B-C-A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with type II diabetes who follow treatment sequence B-C-A. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the second intervention period (Treatment C), then single oral dose of a placebo tablet under fasted conditions in the third intervention period (Treatment A). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1193397/Placebo (sequence B-A-C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with type II diabetes who follow treatment sequence B-A-C. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of a placebo tablet in the second intervention period (Treatment A), then 5 mg BAY1193397 IR tablet under fasted conditions in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1193397</intervention_name>
    <description>Single dose of 1 mg BAY1193397 given in the fasted state</description>
    <arm_group_label>BAY1193397/Placebo (sequence A-B-C)</arm_group_label>
    <arm_group_label>BAY1193397/Placebo (sequence B-A-C)</arm_group_label>
    <arm_group_label>BAY1193397/Placebo (sequence B-C-A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1193397</intervention_name>
    <description>Single dose of 5 mg BAY1193397 given in the fasted state</description>
    <arm_group_label>BAY1193397/Placebo (sequence A-B-C)</arm_group_label>
    <arm_group_label>BAY1193397/Placebo (sequence B-A-C)</arm_group_label>
    <arm_group_label>BAY1193397/Placebo (sequence B-C-A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo given in the fasted state</description>
    <arm_group_label>BAY1193397/Placebo (sequence A-B-C)</arm_group_label>
    <arm_group_label>BAY1193397/Placebo (sequence B-A-C)</arm_group_label>
    <arm_group_label>BAY1193397/Placebo (sequence B-C-A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The informed consent must be signed before any study specific tests or procedures are&#xD;
             done (patient must be able to give informed consent, no legal representative allowed)&#xD;
&#xD;
          -  Patients with a diagnosis of type II diabetes mellitus and PAD (peripheral artery&#xD;
             disease) and/or microangiopathy as evidenced by at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               1. TBPI (toe / brachial blood pressure index) &lt; 0.7 at screening&#xD;
&#xD;
               2. ischemic or neuro-ischemic DFU (diabetic food ulcer) in medical history (verified&#xD;
                  by medical records)&#xD;
&#xD;
               3. clinical diagnosis of PAD in medical history (verified by medical records)&#xD;
&#xD;
               4. diagnosis of nephropathy that is most likely due to diabetes mellitus type II&#xD;
&#xD;
               5. diagnosis of diabetic retinopathy&#xD;
&#xD;
               6. diagnosis of diabetic polyneuropathy&#xD;
&#xD;
          -  Age 55 to 75 years (inclusive) at the screening visit&#xD;
&#xD;
          -  Non-smokers are preferred for inclusion in this study. If smokers are included, they&#xD;
             must refrain from smoking on the days of treatment periods 1, 2, and 3 until all&#xD;
             examinations have been performed&#xD;
&#xD;
          -  Patients are expected to be on stable medication during study conduct. No planned&#xD;
             changes in drug therapy during active treatment period of the study (i.e. from&#xD;
             treatment period 1 to treatment period 3) is allowed.&#xD;
&#xD;
          -  Men or confirmed postmenopausal women (defined as exhibiting spontaneous amenorrhea&#xD;
             for at least 12 months before screening or as exhibiting spontaneous amenorrhea for 6&#xD;
             months before screening with documented serum follicle-stimulating hormone [FSH]&#xD;
             levels &gt; 40 mIU/mL) or women without childbearing potential based on surgical&#xD;
             treatment 6 weeks before screening such as bilateral tubal ligation, bilateral&#xD;
             oophorectomy with or without hysterectomy (documented by medical report verification).&#xD;
             Male patients, who are sexually active and have not been surgically sterilized must&#xD;
             agree to use two reliable and acceptable methods of contraception simultaneously (one&#xD;
             method used by the study patient and one method used by the partner) during the study&#xD;
             and for 12 weeks after receiving the investigational medicinal product and not to act&#xD;
             as sperm donor for 12 weeks after dosing. Acceptable methods of contraception include&#xD;
             for example: a) condoms (male or female) with or without a spermicidal agent b)&#xD;
             diaphragm or cervical cap with spermicide c) intrauterine device d) hormone-based&#xD;
             contraception&#xD;
&#xD;
          -  Ability to understand and follow study related instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with existing lower limb ulcers&#xD;
&#xD;
          -  Patients with nailfold capillaries at the great toe that are technically difficult to&#xD;
             assess&#xD;
&#xD;
          -  Patients suffering from PAD Fontaine Stage 4&#xD;
&#xD;
          -  Patients requiring planned revascularization&#xD;
&#xD;
          -  Patients suffering from diseases other than diabetes mellitus that are known to lead&#xD;
             to disturbances in skin microcirculation or interfering with the method of measurement&#xD;
             such as Raynaud's disease, collagen vascular disorders , atopic dermatitis, psoriasis&#xD;
&#xD;
          -  Myocardial infarction, acute coronary syndrome, transient ischemic attack (TIA),&#xD;
             stroke, revascularization, angioplasty within 3 months prior to randomization&#xD;
&#xD;
          -  Any planned surgical intervention during the course of the study&#xD;
&#xD;
          -  Medical condition or history thereof or any deviation from normal laboratory values&#xD;
             that in the opinion of the investigator would impair the ability to complete the&#xD;
             planned study procedures.&#xD;
&#xD;
          -  Any surgical or medical condition which significantly alters absorption, distribution,&#xD;
             metabolism or excretion of study drugs, including, but not limited to: history of&#xD;
             major gastrointestinal (GI) tract surgery, inflammatory bowel disease, currently&#xD;
             active gastritis, pancreatitis, treatment with cholestyramine and colestipol resins&#xD;
&#xD;
          -  Patients with HbA1c &gt; 12% (&gt; 108 mmol/mol) at the screening visit&#xD;
&#xD;
          -  Any other condition or therapy, which would make the subject unsuitable for this study&#xD;
             and will not allow participation for the full planned study period (e.g. active&#xD;
             malignancy or other condition limiting life expectancy to less than 12 months)&#xD;
&#xD;
          -  Use of alpha- or beta-AR (adrenoreceptor) agonists&#xD;
&#xD;
          -  Use of alpha-AR antagonists&#xD;
&#xD;
          -  Use of serotonin/norepinephrine reuptake inhibitors (SNRIs)&#xD;
&#xD;
          -  Use of tricyclic antidepressants at a dose equivalent of more than 50 mg amitryptyline&#xD;
&#xD;
          -  No pedicure or nail polish is allowed from screening until the end of the active study&#xD;
             period (end of treatment period 3)&#xD;
&#xD;
          -  Systolic blood pressure below 100 mmHg or above 180 mmHg at the screening visit based&#xD;
             on the average of three readings taken from the arm with the highest systolic&#xD;
             recordings&#xD;
&#xD;
          -  Diastolic blood pressure below 50 or above 110 mmHg at the screening visit based on&#xD;
             the average of three readings taken from the arm with the highest systolic recordings&#xD;
&#xD;
          -  Heart rate below 50 or above 100 beats/min at screening (obtained from ECG)&#xD;
&#xD;
          -  Clinically relevant findings in the physical examination which, in the opinion of the&#xD;
             investigator, preclude participation for reasons of the patient's safety&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m^2 using the Modification&#xD;
             of Diet in Renal Disease (MDRD) formula at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 21, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

